Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028374 · ClinicalTrials.gov registry record · Phase 2
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05028374 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 119 participants.
The verdict
NCT05028374, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were authorized for use in the USA. Researchers will also assess whether the booster dosing with the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other blood cancers.
Interventions
- DRUG A single "booster" dose of the Moderna mRNA COVID-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05028374
The ClinicalTrials.gov registry entry for NCT05028374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A single "booster" dose of the Moderna mRNA COVID-19 vaccine is the first listed.
NCT05028374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05028374 about?
NCT05028374 is a clinical study titled "COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies". To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were authorized for use in the USA....
What is the current status of trial NCT05028374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2021-08-17. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT05028374?
The interventions under investigation include: A single "booster" dose of the Moderna mRNA COVID-19 vaccine (DRUG).
Who is sponsoring clinical trial NCT05028374?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.